MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Blood Processing, Blood Pumps, Diagnostics, Hemorrhage, Bleeding, Hemostatis, Transfusion, Intravenous (IV) Management
CytoSorbents Corporation (NASDAQ:CTSO)*
Organization & Developments: Cytosorbents
Parents
CytoSorbents Corporation (NASDAQ:CTSO)*
Children
*Advanced blood purification to reduce cytokine storm and inflammation leading to multi-organ failure, sepsis and critical care
*CytoSorbent's products are comprised of porous, adsorbent polymer beads that target molecules up to 50,000 Daltons, such as pro-inflammatory and anti- inflammatory cytokines
*CytoSorbents Corporation
*CytoSorbents Inc. is a medical device company that has developed a new adsorbent platform technology for removal of toxins from blood and physiologic fluids.
*Cytosorbents specializes in blood purification to control deadly inflammation in critically-ill and cardiac surgery patients.
2011: Extracorporeal CytoSorb Cytokines Filter Gets European Approval (2011)
2017: Biotech Forum Daily Digest: Update On Approximately $5 Cytosorbents
2017: CytoSorbents on go with pivotal study of CytoSorb in cardiac surgery; shares up 4% - Cytosorbents Corp (NASDAQ:CTSO)
2017: Cytosorbents: A Razor & Razor Blade Story - Cytosorbents Corp (NASDAQ:CTSO)
2017: Its primary product CytoSorb is approved in the European Union and distributed in over 40 countries (but not the United States).
2018: Current View On Cytosorbents_seekingalpha.com
2018: CytoSorbents Expands Its Partnership with Biocon to Launch CytoSorb® in Malaysia
2019: Cytosorbents: Looking Closer At 'Survival Benefit' Of Cytosorb In Septic Shock_seekingalpha.com
2020: Cytosorbents: Concentration Risk With Covid-19 Overexposure
2021: Cytosorbents: Endocarditis Trial Failed To Remove Risk In Heart Surgery Patients
2021: Second U.S. FDA Breakthrough Device Designation Granted to CytoSorbents' DrugSorb-ATR™ Antithrombotic Removal System Adding the Removal of Market-Leading Direct Oral Anticoagulants During Urgent Cardiothoracic Surgery
2022: CytoSorbents wins $2M Defense Department award
2025: Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025
Jumps
*Key People: Cytosorbents
Finance & Acquisition: Cytosorbents